\-\ Texto\\:\\ \ \(0\)\
\-\ pe\\ unremarkable\\.\\ \ \(0\)\
\-\ cbc\\:\\ 8\\.7\\>14\\.4\\/42\\.3\\<223\ \(0\)\
\-\ bmp\\:\\ 146\\/4\\.5\\/111\\/28\\/24\\/0\\.8\\<91\ \(0\)\
\-\ ua\\:\\ 10\\ rbc\\,\\ \\>100\\ wbc\\,\\ nitrites\\ negative\ \(0\)\
\-\ right\\ radical\\ nephroureterectomy\\/cystoprostatectomy\\ with\\ ileal\\ conduit\ \(0\)\
\-\ bilateral\\ nephrolithiasis\\ with\\ a\\ stone\\ in\\ the\\ proximal\\ right\\ ureter\\ causing\\ obstruction\\ of\\ the\\ right\\ collecting\\ system\\.\\ \\ surrounding\\ enhancing\\ soft\\ tissue\\ density\\ around\\ this\\ stone\\ suggestive\\ of\\ an\\ adjacent\\ mass\\ suspicious\\ for\\ an\\ upper\\ tract\\ lesion\\.\ \(0\)\
\-\ transitional\\ cell\\ carcinoma\\ \\(t2\\ low\\ grade\\ papillary\\ urothelial\\ carcinoma\\)\ \(0\)\
\-\ neoplasm\ \(440\)\
\-\ obstructing\\ stone\ \(10\)\
\-\ infected\\ stone\ \(0\)\
\-\ uti\ \(1153\)\
\-\ 70\\ year\\ old\\ male\\ with\\ history\\ of\\ high\\ grade\\ t1\\ papillary\\ urothelial\\ carcinoma\\ in\\ 2008\\ currently\\ undergoing\\ bcg\\ therapy\\ now\\ with\\ new\\ onset\\ gross\\ hematuria\\ and\\ right\\ sided\\ flank\\ pain\\.\\ denies\\ fevers\\,\\ chills\\,\\ dysuria\\ or\\ other\\ gu\\ symptoms\\.\ \(0\)\
\-\ hematuria\\ work\\-up\\ consists\\ of\\ three\\ \\(3\\)\\ studies\\:\\ 1\\.\\ urine\\ cytology\\,\\ 2\\.\\ ct\\ abdomen\\/pelvis\\ with\\/without\\ contrast\\ \\(ct\\ renal\\ ivp\\,\\ triple\\ phase\\ ct\\,\\ hematuria\\ protocol\\ ct\\)\\,\\ and\\ 3\\.\\ cystoscopy\\.\\ \ \(0\)\
\-\ epidemiology\\ of\\ tcc\\:\ \(0\)\
\-\ \\ \\-\\ accounts\\ for\\ \\~90\\%\\ of\\ all\\ gu\\ cancers\ \(0\)\
\-\ \\ \\-\\ can\\ be\\ multifocal\\ and\\ bilateral\ \(0\)\
\-\ \\ \\-\\ aa\\ \\>\\ caucasian\\ \\=\\ hispanic\\ \\=\\ native\\ americans\\ \\>\\ asians\ \(0\)\
\-\ \\ \\-\\ male\\:female\\ \\ 2\\:1\ \(0\)\
\-\ \\ \\-\\ peak\\ incidence\\ 60\\-70\\ years\\,\\ rarely\\ before\\ 40\ \(0\)\
\-\ \\ \\-\\ bladder\\ \\>\\>\\ upper\\ urinary\\ tract\ \(0\)\
\-\ \\ \\-\\ risk\\ factors\\:\\ smoking\\,\\ exposure\\ to\\ numerous\\ chemical\\ compounds\\ \\(aniline\\ dyes\\,\\ pvc\\)\\,\\ chemotherapy\\,\\ chronic\\ bacterial\\ or\\ schistosomiasis\\ gu\\ infection\\ and\\ stones\\ \\(usually\\ causes\\ scc\\)\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ \\>\\:\\ 0\\.06814002035204554\ \(0\)\
\-\ stone\\:\\ 0\\.0680187237199786\ \(0\)\
\-\ gu\\:\\ 0\\.06715971118917957\ \(0\)\
\-\ urothelial\\:\\ 0\\.05210346664777962\ \(0\)\
\-\ \\-\\:\\ 0\\.05128839684383418\ \(0\)\
\-\ hematuria\\:\\ 0\\.04864013387002491\ \(0\)\
\-\ \\=\\:\\ 0\\.03587828066944134\ \(0\)\
\-\ 14\\.4\\/42\\.3\\:\\ 0\\.035262073695865995\ \(0\)\
\-\ 146\\/4\\.5\\/111\\/28\\/24\\/0\\.8\\:\\ 0\\.035262073695865995\ \(0\)\
\-\ nephroureterectomy\\/cystoprostatectomy\\:\\ 0\\.035262073695865995\ \(0\)\
\-\ \\~90\\:\\ 0\\.035262073695865995\ \(0\)\
\-\ aniline\\:\\ 0\\.035262073695865995\ \(0\)\
\-\ dyes\\:\\ 0\\.035262073695865995\ \(0\)\
\-\ papillary\\:\\ 0\\.03470545287590633\ \(0\)\
\-\ conduit\\:\\ 0\\.03248948497362621\ \(0\)\
\-\ pvc\\:\\ 0\\.03248948497362621\ \(0\)\
\-\ \\:\\:\\ 0\\.03164769484773862\ \(0\)\
\-\ 223\\:\\ 0\\.030867624541193555\ \(0\)\
\-\ with\\/without\\:\\ 0\\.030867624541193555\ \(0\)\
\-\ asians\\:\\ 0\\.030867624541193555\ \(0\)\
\-\ tract\\:\\ 0\\.030280644020592502\ \(0\)\
\-\ bcg\\:\\ 0\\.029716896251386432\ \(0\)\
\-\ compounds\\:\\ 0\\.029716896251386432\ \(0\)\
\-\ carcinoma\\:\\ 0\\.029063132040190398\ \(0\)\
\-\ ivp\\:\\ 0\\.028095035818953774\ \(0\)\
\-\ cystoscopy\\:\\ 0\\.028095035818953774\ \(0\)\
\-\ 8\\.7\\:\\ 0\\.02747843309964474\ \(0\)\
\-\ nitrites\\:\\ 0\\.02747843309964474\ \(0\)\
\-\ native\\:\\ 0\\.02747843309964474\ \(0\)\
\-\ 60\\-70\\:\\ 0\\.02747843309964474\ \(0\)\
\-\ americans\\:\\ 0\\.02694430752914665\ \(0\)\
\-\ 2\\:1\\:\\ 0\\.02694430752914665\ \(0\)\
\-\ tcc\\:\\ 0\\.026473175386521115\ \(0\)\
\-\ \\<\\:\\ 0\\.026384524220014326\ \(0\)\
\-\ grade\\:\\ 0\\.02603869434360776\ \(0\)\
\-\ schistosomiasis\\:\\ 0\\.02532244709671399\ \(0\)\
\-\ epidemiology\\:\\ 0\\.02470584437740496\ \(0\)\
\-\ scc\\:\\ 0\\.024429872891457153\ \(0\)\
\-\ 91\\:\\ 0\\.023484317779200233\ \(0\)\
\-\ cytology\\:\\ 0\\.0230839839449723\ \(0\)\
\-\ triple\\:\\ 0\\.0230839839449723\ \(0\)\
\-\ ileal\\:\\ 0\\.02289790388243273\ \(0\)\
\-\ bmp\\:\\ 0\\.022549858374474208\ \(0\)\
\-\ abdomen\\/pelvis\\:\\ 0\\.022549858374474208\ \(0\)\
\-\ dysuria\\:\\ 0\\.022229687543780064\ \(0\)\
\-\ aa\\:\\ 0\\.021933255655165178\ \(0\)\
\-\ uti\\:\\ 0\\.02165728416921737\ \(0\)\
\-\ hispanic\\:\\ 0\\.02165728416921737\ \(0\)\
\-\ accounts\\:\\ 0\\.02152612487792541\ \(0\)\
\-\ radical\\:\\ 0\\.021399130084667085\ \(0\)\
\-\ chemical\\:\\ 0\\.02104068144990834\ \(0\)\
\-\ transitional\\:\\ 0\\.020927997942041553\ \(0\)\
\-\ infected\\:\\ 0\\.020818402045289095\ \(0\)\
\-\ cancers\\:\\ 0\\.02060782711134741\ \(0\)\
\-\ obstructing\\:\\ 0\\.020506555879410245\ \(0\)\
\-\ nephrolithiasis\\:\\ 0\\.020125315160192947\ \(0\)\
\-\ 2008\\:\\ 0\\.01977726965223443\ \(0\)\
\-\ rbc\\:\\ 0\\.019694792503423486\ \(0\)\
\-\ peak\\:\\ 0\\.019457098821540283\ \(0\)\
\-\ work\\-up\\:\\ 0\\.019306137509608894\ \(0\)\
\-\ ct\\:\\ 0\\.019124858454272687\ \(0\)\
\-\ consists\\:\\ 0\\.018753536155685625\ \(0\)\
\-\ ureter\\:\\ 0\\.01844330321830213\ \(0\)\
\-\ protocol\\:\\ 0\\.018384042875161564\ \(0\)\
\-\ multifocal\\:\\ 0\\.018384042875161564\ \(0\)\
\-\ ua\\:\\ 0\\.01815540921980177\ \(0\)\
\-\ exposure\\:\\ 0\\.017784282285997908\ \(0\)\
\-\ stones\\:\\ 0\\.0175867112646796\ \(0\)\
\-\ bacterial\\:\\ 0\\.01749146866990473\ \(0\)\
\-\ collecting\\:\\ 0\\.01744468451085196\ \(0\)\
\-\ 100\\:\\ 0\\.017262835014544932\ \(0\)\
\-\ smoking\\:\\ 0\\.017262835014544932\ \(0\)\
\-\ chills\\:\\ 0\\.01708889456678598\ \(0\)\
\-\ undergoing\\:\\ 0\\.016762182442728906\ \(0\)\
\-\ bilateral\\:\\ 0\\.01659054183451555\ \(0\)\
\-\ urine\\:\\ 0\\.016496682166949418\ \(0\)\
\-\ upper\\:\\ 0\\.016496644042949746\ \(0\)\
\-\ suspicious\\:\\ 0\\.016460152232696326\ \(0\)\
\-\ 70\\:\\ 0\\.01642395289061666\ \(0\)\
\-\ rarely\\:\\ 0\\.016388078210685615\ \(0\)\
\-\ caucasian\\:\\ 0\\.016317279902288012\ \(0\)\
\-\ gross\\:\\ 0\\.016282345182412995\ \(0\)\
\-\ fevers\\:\\ 0\\.016247712931440537\ \(0\)\
\-\ flank\\:\\ 0\\.016078911513479028\ \(0\)\
\-\ phase\\:\\ 0\\.016078911513479028\ \(0\)\
\-\ urinary\\:\\ 0\\.015822824078419305\ \(0\)\
\-\ incidence\\:\\ 0\\.015670714496062346\ \(0\)\
\-\ pe\\:\\ 0\\.015355138726183696\ \(0\)\
\-\ factors\\:\\ 0\\.015355138726183696\ \(0\)\
\-\ numerous\\:\\ 0\\.015327647209032649\ \(0\)\
\-\ cbc\\:\\ 0\\.015273224600809533\ \(0\)\
\-\ causing\\:\\ 0\\.014766217778252957\ \(0\)\
\-\ suggestive\\:\\ 0\\.014602929800171938\ \(0\)\
\-\ before\\:\\ 0\\.014468085570802692\ \(0\)\
\-\ \\(\\:\\ 0\\.014447234524877211\ \(0\)\
\-\ right\\:\\ 0\\.014426107345766668\ \(0\)\
\-\ denies\\:\\ 0\\.01442412908450031\ \(0\)\
\-\ 40\\:\\ 0\\.014380650395552695\ \(0\)\
\-\ \\)\\:\\ 0\\.014270753842266101\ \(0\)\
\-\ around\\:\\ 0\\.014232092207754867\ \(0\)\
\-\ \\,\\:\\ 0\\.014076923406898943\ \(0\)\
\-\ bladder\\:\\ 0\\.013873643572996117\ \(0\)\
\-\ currently\\:\\ 0\\.013544691180048229\ \(0\)\
\-\ system\\:\\ 0\\.013457919881603192\ \(0\)\
\-\ causes\\:\\ 0\\.013306322791239247\ \(0\)\
\-\ studies\\:\\ 0\\.01276600367111664\ \(0\)\
\-\ sided\\:\\ 0\\.012638106452586582\ \(0\)\
\-\ wbc\\:\\ 0\\.012460299402303247\ \(0\)\
\-\ risk\\:\\ 0\\.012380826589436346\ \(0\)\
\-\ male\\:\\ 0\\.012361644303099786\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.01225178314056346\ \(0\)\
\-\ obstruction\\:\\ 0\\.012053600194357743\ \(0\)\
\-\ new\\:\\ 0\\.011911151907202234\ \(0\)\
\-\ 3\\.\\:\\ 0\\.011695496848562909\ \(0\)\
\-\ now\\:\\ 0\\.01168446235880659\ \(0\)\
\-\ neoplasm\\:\\ 0\\.011640626303647712\ \(0\)\
\-\ 10\\:\\ 0\\.011522496913387642\ \(0\)\
\-\ three\\:\\ 0\\.011522496913387642\ \(0\)\
\-\ unremarkable\\:\\ 0\\.011316265674728243\ \(0\)\
\-\ density\\:\\ 0\\.011246525427439837\ \(0\)\
\-\ surrounding\\:\\ 0\\.011236661057459062\ \(0\)\
\-\ 2\\.\\:\\ 0\\.010869776567201032\ \(0\)\
\-\ t1\\:\\ 0\\.010833982144896975\ \(0\)\
\-\ adjacent\\:\\ 0\\.010807344976537068\ \(0\)\
\-\ onset\\:\\ 0\\.0107896849037006\ \(0\)\
\-\ enhancing\\:\\ 0\\.010719814131539038\ \(0\)\
\-\ 1\\.\\:\\ 0\\.010676756665190404\ \(0\)\
\-\ usually\\:\\ 0\\.010379713015467036\ \(0\)\
\-\ renal\\:\\ 0\\.010269902197832277\ \(0\)\
\-\ proximal\\:\\ 0\\.010262172726828061\ \(0\)\
\-\ negative\\:\\ 0\\.010208480645499497\ \(0\)\
\-\ years\\:\\ 0\\.01003697254807393\ \(0\)\
\-\ infection\\:\\ 0\\.009936066296291228\ \(0\)\
\-\ t2\\:\\ 0\\.009674355075001409\ \(0\)\
\-\ all\\:\\ 0\\.009667693957725163\ \(0\)\
\-\ chronic\\:\\ 0\\.009627958531628\ \(0\)\
\-\ low\\:\\ 0\\.009504672211465599\ \(0\)\
\-\ an\\:\\ 0\\.00945331891427784\ \(0\)\
\-\ high\\:\\ 0\\.009354184244307263\ \(0\)\
\-\ cell\\:\\ 0\\.009232962846325946\ \(0\)\
\-\ therapy\\:\\ 0\\.009138563184962452\ \(0\)\
\-\ symptoms\\:\\ 0\\.008518629907592556\ \(0\)\
\-\ soft\\:\\ 0\\.0083237070559742\ \(0\)\
\-\ tissue\\:\\ 0\\.008101684753810375\ \(0\)\
\-\ or\\:\\ 0\\.00801218199170966\ \(0\)\
\-\ 3\\:\\ 0\\.00800390210682616\ \(0\)\
\-\ \\%\\:\\ 0\\.00797328413338403\ \(0\)\
\-\ other\\:\\ 0\\.007878554194809794\ \(0\)\
\-\ can\\:\\ 0\\.0077528894098762785\ \(0\)\
\-\ contrast\\:\\ 0\\.007651102747231621\ \(0\)\
\-\ female\\:\\ 0\\.0070270410857913345\ \(0\)\
\-\ lesion\\:\\ 0\\.006962220904001819\ \(0\)\
\-\ for\\:\\ 0\\.005832865189141721\ \(0\)\
\-\ be\\:\\ 0\\.005271026893375717\ \(0\)\
\-\ mass\\:\\ 0\\.004753844027790258\ \(0\)\
\-\ history\\:\\ 0\\.004720858150828334\ \(0\)\
\-\ pain\\:\\ 0\\.0041744326701229385\ \(0\)\
\-\ this\\:\\ 0\\.0038445488532565324\ \(0\)\
\-\ year\\:\\ 0\\.003824421077091659\ \(0\)\
\-\ old\\:\\ 0\\.0034997383874490187\ \(0\)\
\-\ in\\:\\ 0\\.0033711778411220396\ \(0\)\
\-\ and\\:\\ 0\\.0028801440917154953\ \(0\)\
\-\ of\\:\\ 0\\.0027960912191517225\ \(0\)\
\-\ with\\:\\ 0\\.0018720668174382357\ \(0\)\
\-\ to\\:\\ 0\\.001708272433771945\ \(0\)\
\-\ a\\:\\ 0\\.0015863992072744052\ \(0\)\
\-\ the\\:\\ 0\\.0011059942776290065\ \(0\)\
\-\ \\.\\:\\ 0\\.0008519888663363107\ \(0\)\
